RPE65 and retinitis pigmentosa 1: In 2023, the FDA approved voretigene neparvovec (Luxturna), a treatment for RP patients that have mutations in RPE65 (~ 1–2% of RP cases), that introduces a normal copy of RPE65 directly into retinal cells [10].